Vertex creates new possibilities in medicine to cure diseases and improve people's lives.
Mentions
98
Location: United States, Wisconsin, Milwaukee
Mentions in press and media 98
| Date | Title | Description |
| 05.08.2025 | Vertex Falls After FDA Doubts Broad Use of Chronic Pain Drug | - |
| 04.08.2025 | Stocks making the biggest moves after hours: Palantir, Hims & Hers Health, Vertex Pharmaceuticals and more | - |
| 04.08.2025 | S&P 500 futures inch higher after benchmark snaps losing streak, Palantir pops on earnings: Live updates | Stock futures were slightly higher on Monday night, following Wall Street’s rebound, as investors followed the latest batch of corporate earnings. Dow Jones Industrial Average futures added 48 points, or about 0.1%. S&P 500 futures and ... |
| 01.08.2025 | Frazier Life Sciences: $1.3 Billion Venture Fund Closed | Frazier Life Sciences (FLS), an investment firm focused on innovative therapeutics, announced the closing of Frazier Life Sciences XII, L.P. (FLS XII), with over $1.3 billion in capital commitments. The oversubscribed fund received strong s... |
| 29.07.2025 | Trump’s pharmaceutical tariffs could affect some drugmakers more than others | President Donald Trump is slated to impose tariffs on pharmaceuticals imported into the U.S. any day now – and they may have a bigger impact on some drugmakers than others. AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-... |
| 18.06.2025 | The Dawn of Radioligand Therapies: A New Era in Precision Oncology | In the realm of cancer treatment, innovation is the lifeblood that fuels hope. The latest beacon of this hope shines brightly on radioligand therapies (RLTs). These therapies are not just a whisper of potential; they are a clarion call for ... |
| 13.06.2025 | Indianapolis-based startup leans on connections to treat brain diseases | Please subscribe to IBJ to decode this article. so" co7tniifn:wct=l l5m=/nne4bBc_omtI"/ioaedel"-_oii=ii0-edidC5a2ru["00-mca5ae=fud othmtwi1ga"e"3r"daletl0ca]nsene d vy.sdstiheip =loto jee6teo mpts m3t [c6i... |
| 06.06.2025 | JPMorgan’s top biotech and pharma picks for the second half | - |
| 04.06.2025 | Health-care stocks are due for a turnaround after a historically bad month, according to the charts | - |
| 28.05.2025 | These biotech stocks will benefit as generative AI speeds up drug discovery, Jefferies says | - |
| 08.05.2025 | The Rise of AI and Regenerative Medicine: A New Era of Innovation | In the world of technology and healthcare, two stories are unfolding that promise to reshape our future. On one side, Google’s DeepMind has unveiled its latest coding model, Gemini 2.5 Pro I/O Edition. On the other, Stately Bio has secured ... |
| 07.05.2025 | Stately Bio: $12 Million Closed For Developing Regenerative Medicines With Cellular Imaging Platform | Stately Bio, a company developing cell therapies using an ML-based live-cell imaging platform, announced $12 million in seed funding led by AIX Ventures, with participation from Dimension Capital, Foothill Ventures, Village Global, Caffeina... |
| 06.05.2025 | Stocks making the biggest moves premarket: Palantir Technologies, Ford Motor, Vertex Pharmaceuticals, DoorDash and more | - |
| 05.05.2025 | S&P 500 futures are little changed as Wall Street looks to Fed policy meeting: Live updates | S&P 500 futures were little changed Monday night, as investors awaited the start of the Federal Reserve’s first policy meeting since President Donald Trump announced “reciprocal” tariffs in early April. S&P 500 futures flickered nea... |
| 03.05.2025 | Uber's Robotaxi Revolution: A New Era in European Mobility | Uber is steering into the future. The ride-hailing giant has struck a deal with Momenta, a Chinese self-driving startup, to launch a robotaxi service in Europe by early 2026. This partnership is a bold move, merging Uber's extensive ridesha... |
| 02.05.2025 | Cramer’s week ahead: Earnings from Disney, Palantir and Uber | Monday - Friday, 6:00 - 7:00 PM ET CNBC’s Jim Cramer on Friday highlighted the most market-moving events of next week, including earnings reports from Disney, Palantir and Uber. He also remarked on the turbulent nature of the market as of l... |
| 29.04.2025 | Перечень жизненно важных лекарств не резиновый | - |
| 28.04.2025 | Фармрынок идет на поправку | - |
| 15.04.2025 | Назад, в генетическое будущее | - |
| 03.04.2025 | Brander Group Ranks 92 on Financial Times Fastest Growing Companies in 2025 | Brander Group Ranks #92 on Financial Times in 2025 Brander Group ranked #92 on Financial Times list of Americas' Fastest Growing Companies in 2025. Revenue increased 451% over a 3-year period SCOTTSDALE, Ariz., April 3, 2025 /PRNewswire-PRW... |
| 02.04.2025 | Latest Innovation in Automation and AI/ML Presented at the 11th Annual Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D. Top biopharmas and leading biotechs discuss new trends in AI/ML and share how th... |
| 01.04.2025 | Trump’s tariffs are a new challenge for Big Pharma. Here are the best-positioned stocks | - |
| 27.03.2025 | Jim Cramer says 'the market may be far healthier than we think.' Here's why | Monday - Friday, 6:00 - 7:00 PM ET The indexes finished another day in the red after investors respond to new auto tariff policies. Jim Cramer highlighted three distinct sectors where stocks rallied and suggested the market isn't as grim as... |
| 22.03.2025 | America needs a jab in its corporate backside | - |
| 21.03.2025 | NVIDIA GTC: AI Innovation Driving Change in Healthcare and Drug Discovery | - |
| 20.03.2025 | The aging population is a $1 trillion opportunity. These stocks are the winners, says Mizuho | - |
| 12.03.2025 | Выпускайте субстанцию: фарма ищет лучшую версию себя | - |
| 25.02.2025 | The Future of Advanced Therapeutics: Opportunities and Challenges | Sai Bhamidipati, Pharmaceutical Regulatory Affairs Consultant The biopharmaceutical landscape is transforming with the advent of advanced therapeutics, including mRNA vaccines, gene therapies, and personalized medicine. These innovative tre... |
| 21.02.2025 | Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker | Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million. Bluebird makes three gene therapies: Zynteglo for beta thalassemia, Lyfgenia for sickle cell disease and Skysona for cerebral adrenoleukodys... |
| 20.02.2025 | JPMorgan’s top biopharma picks for 2025 | - |
| 11.02.2025 | Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand | Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand By ReutersFebruary 10, 20259:13 PM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link A sign hangs in front of the world headq... |
| 24.12.2024 | SiteOne Therapeutics: A New Dawn in Non-Opioid Pain Management | In a world where pain management often leads to addiction, SiteOne Therapeutics is carving a new path. The San Francisco-based biotech has just secured $100 million in Series C funding, led by Novo Holdings. This investment marks a signific... |
| 18.12.2024 | Novo Holdings leads SiteOne's $100M series C for non-opioid pain treatments | SiteOne Therapeutics is powering up with $100 million to advance its early pipeline of non-opioid therapeutics that target the peripheral nervous system instead of the central nervous system. The biotech’s series C financing was led by Novo... |
| 09.11.2024 | The Rising Tide of Biotech: Boston's Role in Global Health Transformation | Boston's biotech industry is a lighthouse in the stormy seas of global health challenges. It shines brightly, guiding innovation and collaboration. This city, with its prestigious universities and a vibrant network of biotech firms, has bec... |
| 04.11.2024 | The Impact of Boston’s Biotech Industry on Global Health | Share Tweet Share Share Email The biotech industry in Boston is more than just a source of jobs or a pillar of the local economy; it is a powerful force in the global fight for better health. Known for its prestigious universities, research... |
| 01.11.2024 | CRISPR and Gene Editing: How Boston is Leading in Biotech | Share Tweet Share Share Email Boston has become one of the top places for biotech research, and one of the big players in this space is CRISPR gene-editing technology. CRISPR is creating exciting opportunities in everything from medicine to... |
| 29.10.2024 | Tolerance Bio: $17.2 Million (Seed) Raised To Increase Healthspan By Manipulating Thymus Functions | Tolerance Bio, a biopharmaceutical company pioneering a novel approach to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, announced the closing of its ov... |
| 20.10.2024 | Tolerance Bio: Pioneering the Future of Immune Health with $17.2 Million Seed Funding | In the world of biopharmaceuticals, innovation is the lifeblood. Tolerance Bio, a Philadelphia-based company, has just secured $17.2 million in seed funding. This financial boost is not just a number; it represents a beacon of hope for many... |
| 20.10.2024 | Tolerance Bio: $17.2 Million (Seed) Raised For Increasing Healthspan By Adjusting Function Of The Thymus | Tolerance Bio – a biopharmaceutical company pioneering a novel approach to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance – announced the closing of its ... |
| 04.10.2024 | Frazier Life Sciences: Over $630 Million Added To Evergreen Public Fund | Frazier Life Sciences (FLS), a healthcare investment firm focused on innovative therapeutics, announced it has closed on over $630 million in capital commitments to its evergreen Public Fund from new and existing investors in an oversubscri... |
| 26.09.2024 | Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say | Future of HealthRegulatory Oversight Commercial Strategy Regulatory Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say By Kashish Tandon and Christy SanthoshSeptember 26, 20243:40 PM UTCUpdated ago... |
| 18.09.2024 | Safi Biotherapeutics: Manufactured Red Blood Cells Company Raises $5 Million (Seed) | Safi Biotherapeutics—a company launched by former DARPA, Vertex, MIT, and MGH leaders—is leading the development of manufactured red blood cells (mRBCs) as an alternative to donor blood transfusions. The company recently announced a $5 mill... |
| 14.09.2024 | The Future of Scent: Osmo's Scientific Advisory Board and Its Implications | In a world where technology and biology intertwine, Osmo is carving a niche in the realm of digital olfaction. The company recently announced the formation of its Scientific Advisory Board (SAB), a powerhouse of experts from diverse fields.... |
| 12.09.2024 | Osmo Announces Launch of Scientific Advisory Board | NEW YORK, Sept. 12, 2024 /PRNewswire/ -- The digital olfaction company, Osmo, today announced the formation of its Scientific Advisory Board (SAB) composed of leading experts in synthetic chemistry, analytical chemistry, artificial intellig... |
| 03.09.2024 | Pharmaceutical Market: Trends, Segmentation, and Growth Opportunities | Share Tweet Share Share Email In recent years, the pharmaceutical market has witnessed remarkable growth and transformation, driven by technological advancements, evolving consumer needs, and the global push for better healthcare solutions.... |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 16.07.2024 | Genomics plc Expands Drug Discovery Collaboration with Vertex | What You Should Know: –Genomics plc (Genomics), a healthcare company transforming health through the power of genomics today announced a three-year extension of the company’s collaboration with Vertex Pharmaceuticals Incorporated (Vertex) (... |
| 25.06.2024 | Breakthrough T1D-Funded Research Featured at American Diabetes Association 84th Scientific Sessions | NEW YORK, June 25, 2024 /PRNewswire/ -- Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, gathered with researchers, diabetes professionals, and other leaders in T1D at the America... |
| 20.06.2024 | Winners of 2024 BostonCISO ORBIE Awards Announced By BostonCISO | Executives from Vertex Pharmaceuticals, Teradyne, Agero, Draper, and Appfire Recognized for their Achievements. BOSTON, June 20, 2024 /PRNewswire-PRWeb/ -- BostonCISO announced the winners of its 2024 ORBIE® Awards. BostonCISO recognized te... |
| 30.05.2024 | US, UK in focus as pharma companies eye $31 billion exports in FY25 | - |
| 06.05.2024 | NEW ENGLAND PATRIOTS QUARTERBACK DRAKE MAYE NAMED HONORARY CHAIR OF 25TH ANNIVERSARY BEST BUDDIES CHALLENGE: HYANNIS PORT PRESENTED BY JERSEY MIKE'S SUBS, SHAW'S AND STAR MARKET FOUNDATION AND THE TJX... | BOSTON, May 6, 2024 /PRNewswire/ -- Best Buddies International, a nonprofit dedicated to creating opportunities for one-to-one friendships, integrated employment, leadership development, inclusive living, and family support for people with ... |
| 27.04.2024 | India becoming attractive for clinical trials, says pharma industry leaders | - |
| 24.04.2024 | Govt expands committee for drugs, medical devices pricing reforms | - |
| 23.04.2024 | VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES | Vertex obtains an exclusive license to TreeFrog's C-StemTM manufacturing technology in type 1 diabetes TreeFrog and Vertex to collaborate on scale-up of fully differentiated, insulin-producing pancreatic islet cells BOSTON and BORDEAUX, Fra... |
| 23.04.2024 | VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES | Vertex obtains an exclusive license to TreeFrog's C-StemTM manufacturing technology in type 1 diabetes TreeFrog and Vertex to collaborate on scale-up of fully differentiated, insulin-producing pancreatic islet cells BOSTON and BORDEAUX, Fra... |
| 15.04.2024 | Women of Influence: Health Care 2024 – Ileana Hernandez | - |
| 14.03.2024 | 10 прорывных разработок 2024 года по версии MIT Technology Review | Источник: MIT Technology Review Начиная с 2001 года журнал Массачусетского технологического института MIT Technology Review ежегодно публикует свой список из 10 многообещающих технологий, которые, по мнению редакции, способны изменить мир в... |
| 13.03.2024 | После вмешательства генпрокурора РФ 68 южноуральцев обеспечены лекарствами | - |
| 12.01.2024 | CRISPR advances Sickle Cell disease treatment | The innovative gene-editing technique, CRISPR, has made a remarkable leap from laboratory research to practical medicine by offering a groundbreaking treatment for sickle-cell disease. This debilitating illness, resulting from two defective... |
| 17.11.2023 | Green light for world’s first CRISPR gene-edited therapy | |
| 03.11.2023 | State Prescription Drug Affordability Boards could end up limiting access to the life-saving cystic fibrosis medication Trikafta | I was living on the precipice of end-stage disease when I enrolled in the clinical trial that resulted in the historically fast Food and Drug Administration approval for the game-changing cystic fibrosis drug Trikafta. Five years later, the... |
| 28.03.2023 | Up to $230 million for CRISPR Therapeutics | |
| 22.08.2022 | Claire’s Place Foundation Rolls Out Award-Winning Glow Ride | “The glowing reviews of our Glow Ride from participants and media would make my daughter, Claire, so proud,” said Claire’s Place Foundation Executive Director Melissa Yeager. LOS ANGELES (PRWEB) August 22, 2022 Claire’s Place Foundation, a ... |
| 19.04.2022 | Sionna unveils with $111M series B to pursue quest for 'holy grail' cystic fibrosis target | After spending more than two years in stealth mode, Sionna Therapeutics is unveiling with $111 million in series B funds to catapult its cystic fibrosis pipeline and take on market leader Vertex Pharmaceuticals. Having raised roughly $150 m... |
| 27.01.2022 | Vertex Pharmaceuticals : Q4 2021 Presentation | FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS JANUARY 26, 2022 ©2022 Vertex Pharmaceuticals Incorporated AGENDA Introduction Michael Partridge, Senior Vice President, Investor Relations CEO Perspective and Pipeline Update Reshma Kewal... |
| 02.11.2021 | Q3 2021 Presentation | THIRD-QUARTER 2021 FINANCIAL RESULTS NOVEMBER 2, 2021 ©2021 Vertex Pharmaceuticals Incorporated AGENDA Introduction Michael Partridge, Senior Vice President, Investor Relations CEO Perspective and Pipeline Update Reshma Kewalramani, M.D., C... |
| 09.08.2021 | Put Your Glow On: Bike, Roller Skate, Skateboard & Snap Glowing Photos in Hermosa Beach on August 21st | “Our Glow Ride event is vital to raising funds to help vulnerable families with cystic fibrosis," said Claire’s Place Foundation Executive Director Melissa Yeager. "Claire would be absolutely thrilled to know that we continue to g... |
| 25.03.2021 | Meatable banks $47m from DSM, others to realize the pluri-potential of its cellular pork & beef | Netherlands foodtech startup Meatable plans to expand its portfolio of cell-cultured pork and beef products following the close of its $47 million Series A round, co-founder and chief technology officer Daan Luining told AFN. New investors ... |
| 24.03.2021 | Dutch lab-grown meat startup Meatable raises €39.68M to bring its first products to market | Dutch lab-grown meat startup, Meatable, has raised $47M (approx €39.68M) in its Series A round of funding. With this, the company’s total funding has reached $60M (approx €50.66M), to date. The round was led by Dr. Rick Klausner, Section 32... |
| 03.12.2020 | Claire’s Place Foundation Receives Grant From Vertex Pharmaceuticals for Work Proudly Program | “The program is so needed and timely and we are honored that Vertex, a global biotechnology company, as well as independent organizations and individuals all recognize this urgent need in our community," said Claire’s Place Foundation ... |
| 14.03.2020 | The Vertex Foundation Donates $500K to Partners HealthCare to Support COVID-19 Outbreak Response | Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that the Vertex Foundation, a nonprofit charitable foundation, is making a $500k gift to Partners HealthCare, a Boston-based nonprofit hospital and physician network, to support t... |
| 03.09.2019 | Vertex to Acquire Semma for $950M | BOSTON & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 3, 2019– Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the company has entered into a definitive agreement under which Vertex will acquire Semma Therapeutics, a pr... |
| 04.02.2019 | ‘We’re still waiting’: As cystic fibrosis drugs deliver new hope, not everyone is being swept up by scientific progress | CAMBRIDGE, Mass. — The tiny round one is vitamin K. There’s a gel cap (vitamin D), a two-tone capsule (that one protects his liver), a square pill (generic Singulair), and more — seven pill bottles sharing space on his dresser with a “Crimi... |
| 05.08.2016 | Meet Risa Stack, General Manager at GE Ventures | While GE Ventures does invest in external companies, Risa leads the New Business Creation team There has been a big debate over the last few years over whether the Series A crunch is real or not. What everyone can agree on, though, is that ... |
| 19.07.2016 | MassChallenge Sets Application Date for PULSE@MassChallenge | In this role, Nick will be focused on facilitating active collaboration between high-impact startups and key stakeholders within the healthcare ecosystem, including leading providers, investors, corporates, institutions, and patient advocac... |
| 27.06.2016 | CRISPR Therapeutics Raises Additional $38M | |
| 01.06.2016 | MassChallenge Supports Digital Health Entrepreneurs Through PULSE@MassChallenge | A strategic component of the statewide Digital Health Initiative, founding partners for PULSE@MassChallenge include the Commonwealth of Massachusetts, the City of Boston, the Massachusetts Competitive Partnership, Suffolk Construction, Samu... |
| 27.10.2015 | Lucrative partnering deal for CRISPR | |
| 26.10.2015 | Vertex closes $105M CRISPR gene editing deal | The companies explore how to use CRISPR/Cas9 technology to correct the genetic aberrations found in cystic fibrosis and the other diseases. This new technology is attracting wide interest among the venture investment community, but it’s sti... |
| 23.06.2015 | Five conspicuous omissions from MIT Tech Review’s 50 smartest companies | …we did not have trouble finding big ideas. To make the list, a company must have truly innovative technology and a business model that is both practical and ambitious, with the result that it has set the agenda in its field over the past 1... |
| 15.06.2015 | #BIO2015: Are venture capitalists too focused on the science? | Things have changed, Boger said, speaking with a panel of storied biotech entrepreneurs at this week’s BIO convention in Philadelphia. Venture firms are hedging their bets these days with biotech investment – targeting late stage startups, ... |
| 21.04.2015 | That Time Sony’s CEO Wanted to Launch a Weed Tech Startup | Sony Pictures Entertainment CEO Michael Lynton wanted to develop a new chemical additive to marijuana that would be detectable in urine or blood during a roadside test for impaired driving, leaked Sony emails from February of 2014 reveal. &... |
| 13.02.2015 | UNC spinout looking to one-up Kalydeco with one-size-fits-all cystic fibrosis therapy | Spyryx has more than $100,000, largely from angel investors, though it also has taken out a loan from the North Carolina Biotechnology Center. Spyryx is aiming to raise a Series A round and also study the drug’s efficacy in COPD, though it’... |
| 06.01.2015 | Venture philanthropy in healthcare is OK as long as black lives matter | The royalty sale is a huge win for the CFF, but this “venture philanthropy” move has raised a litany of concerns – as highlighted in Tuesday’s New York Times opinion piece. The privatization of medical research – and the subsidization of ph... |
| 10.06.2013 | For new Rhode Island firm, peptides hold hope for disease-altering cystic fibrosis treatments | Procaftor, Calista’s lead candidate, is designed to restore function to the CFTR transporter in the lungs and prevent the buildup of thick mucus. President and CEO Andrew Mallon said that preclinical studies have suggested clinical efficacy... |
| 18.01.2012 | #JPM12 takeaway: Big Pharma puts a big hurt on primary care | But beyond the canned corporate remarks, there were some insights to be made. Shane Climie of consultancy Popper and Co. noted the progress of DNA-sequencing technologies. Announcements from Life Technologies (NASDAQ:LIFE) and Illumina (NAS... |
| 08.12.2011 | 4 tips for life sciences companies seeking foundation funding | “Our job is to put the ball in the air, throw the long ball,” he said. Angel investors and venture capitalists are not the only path for companies looking to traverse the so-called valley of death. Life sciences companies have a funding alt... |
| - | Investing in future innovators | At Vertex Pharmaceuticals, we know the value of investing in future innovators who are ready to make their mark on the world — and shape the future of biotech. Our thoughtfully crafted early career programs provide new team members with the... |
| - | For new Rhode Island firm, peptides hold hope for disease-altering cystic fibrosis treatments | It’s been nearly two-and-a-half decades since the gene associated with the inherited disease cystic fibrosis was discovered, paving the way for disease-modifying drugs. In that time, only one such drug has been approved in the U.S. and Euro... |
| - | Five conspicuous omissions from MIT Tech Review’s 50 smartest companies | We know who made the cut in the latest MIT Technology Review list of the 50 Smartest Companies of 2015. But there were a few conspicuous omissions – take Theranos, for instance, or Alexion Pharmaceuticals – from the otherwise meaty list of ... |
| - | UNC spinout looking to one-up Kalydeco with one-size-fits-all cystic fibrosis therapy | Cystic fibrosis has become the poster child for precision medicine – most new therapies are carefully tailored to a CF patient’s genetic makeup. University of North Carolina spinout Spyryx Biosciences is proposing a one-size-fits-all approa... |
| - | Mental checklists, constant vigilance: A day living with type 1 diabetes | No two days are the same. And yet, as humans, we are creatures who thrive on habits and routine, providing us with a sense of manageability in our lives. Meet Nichole Acosta, who has lived with type 1 diabetes (T1D) since she was diagnosed ... |
| - | Venture philanthropy in healthcare is OK as long as black lives matter | In this brave new world of drug development, we’re seeing philanthropic foundations intertwine with industry to bring meds faster to market. But this new model could unfold into a popularity contest, pitting underfunded disorders against me... |
| - | Humanizing drug discovery | On my first day of medical school we were handed an essay written in 1927 by American physician Francis Weld Peabody entitled ‘The Care of the Patient’.[1] Despite being written 95 years ago it remains fresh today. While we think that the r... |
| - | Vertex closes $105M CRISPR gene editing deal | Vertex Pharmaceuticals is getting in on the gene editing game, teaming up with CRISPR Therapeutics in a $105 million partnership. Vertex, the progenitor of leading cystic fibrosis therapeutics like Kalydeco, is investing $75 million in cash... |
| - | 4 tips for life sciences companies seeking foundation funding | Max Wallace, CEO of Accelerate Brain Cancer Cure, uses a football analogy when explaining his foundation’s approach to funding life sciences research. Large companies aren’t getting into the game, which they see as too risky. But the stakes... |
| - | #BIO2015: Are venture capitalists too focused on the science? | Let the venture capitalists do the investing, and the scientists do the science – or so says Joshua Boger, founder and former CEO of Vertex Pharmaceuticals. Things get messy, and progress gets hindered, when the science gets caught in the i... |
| - | #JPM12 takeaway: Big Pharma puts a big hurt on primary care | The JP Morgan Annual Healthcare Conference has become the biggest conference for the industry drawing pharmaceutical and medical device companies, clinical research organizations, and of course, their investors. Over the course of four days... |
Show more